OR WAIT null SECS
Vincent Colicchio, vice president, supply chain and external manufacturing at Dr. Reddy’s Laboratories, discusses how a lack of proper supplier oversight can impact the pharmaceutical industry and the drug supply chain.
Pharmaceutical Technology asked Vincent Colicchio, vice president, supply chain and external manufacturing at Dr. Reddy’s Laboratories, about how a lack of proper supplier oversight can impact the pharmaceutical industry and the drug supply chain.
PharmTech: What types of quality issues can be created by insufficient oversight of material suppliers? Of contract manufacturers?
Colicchio (Dr. Reddy’s): There are several important materials in the pharmaceutical supply chain such as APIs; key starting materials for API production; excipients; purified water; and packaging materials including bottles, closures, vials, and printed components. The types of quality issues that can be created by insufficient oversight of material suppliers that could impact the supply chain include the following examples:
The types of quality issues that can be created by insufficient oversight of contract manufacturers include failure to ensure that the contract manufacturer thoroughly addressed all open observations found in an FDA inspection or other regulatory agency inspection in a timely manner.
While there are a wide variety of potential issues in this category, it is particularly important that the contract manufacturers properly operate and sanitize the purified water system that is used for production operations and cleaning purposes. Prevention of any microbial contamination is a must in any purified water system. It is also critical that the HVAC systems properly function to maintain production room conditions for temperature and humidity control along with differential pressures at all times.
PharmTech: How is the supply chain impacted by poor oversight of suppliers?
Colicchio (Dr. Reddy’s): The supply chain can be impacted by poor oversight of contract manufacturers. For example, in the event that a contract manufacturer fails to properly clean the production equipment or execute its cleaning validation program, it runs the risk of allowing residues or contaminants to enter into the production process and product. If this occurs, analytical testing would reveal the presence of contaminants. The product would be placed in quarantine until such time that the investigation is carried out and completed with the appropriate [corrective and preventive actions] CAPA. The equipment would need to be re-cleaned. Presuming the original batch fails product release, the product would need to be manufactured again and then shipped to the customer. The delayed shipment of the product to the customer would likely impact on-time and in-full product shipment to the customers and subsequently access to the patients.
Susan Haigney is managing editor of Pharmaceutical Technology.
Vol. 45, No. 9
When referring to this article, please cite it as S.Haigney, “The Impact of Insufficient Oversight,” Pharmaceutical Technology, 45 (9) 2021.